Compare Natera Inc. Common Stock (NTRA) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Invesco NASDAQ 100 ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Invesco NASDAQ 100 ETF trades at $297.24 (market cap $111.77B). The key difference: Invesco NASDAQ 100 ETF is the larger of the two by market cap, and Invesco NASDAQ 100 ETF is more actively traded (2,346,098 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Invesco NASDAQ 100 ETF for 56 Days on average.
| NTRA | QQQM | |
|---|---|---|
Market Cap | $57.03B | $111.77B |
Volume | 1,131,157 | 2,346,098 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $312.76 |
52-Week Low | $179.42 | $229.87 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
QQQM trades at $306.18, down 0.33% with a bullish technical signal from moving averages. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads may offset this benefit. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show neutral oscillators with key support at $304-$306 and resistance at $308-$310.
QQQM offers exposure to Nasdaq-100 growth stocks with competitive fees, but faces competition from alternatives like SCHG and QQQE. The ETF's performance depends on technology sector leadership, with concentration risk in top holdings. Recent news highlights tax implications of similar ETFs, emphasizing the importance of understanding distribution characteristics for long-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
